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Introduction
Myeloproliferative diseases (MPD) and myelodysplastic syn-
dromes (MDS) are a heterogeneous group of chronic myeloid
disorders diagnosed in over 20,000 patients annually in the
United States (Tefferi, 2001).The bone marrow (BM) shows nor-
mal or increased cellularity in MDS, but is always hypercellular
in MPD. Whereas the percentage of blasts at diagnosis ranges
from 1%–20% in MDS, it is normal (<5%) in early stage MPD. In
MDS, there is morphological evidence of BM myeloid dysplasia
usually accompanied by cytopenias, while in MPD there is rela-
tively normal myeloid maturation with an overproduction of cir-
culating myeloid elements and an elevated risk of thrombosis.
By contrast, acute myeloid leukemia (AML) is characterized by
an excess of bone marrow blasts with defective production of
mature cells (Gilliland and Tallman, 2002). MPD and MDS are
characterized by clonal hematopoiesis and an increased risk of
developing acute leukemia, but the frequency of malignant pro-
gression and overall prognosis varies greatly between different
subtypes. In the past decade, there have been major advances
in our understanding of the pathogenesis and treatment of
these diseases.
Myeloproliferative diseases
Classification, clinical features, and epidemiology of the
MPDs
The World Health Organization (WHO) classification of MPDs
(Vardiman et al., 2002) includes chronic myeloid leukemia
(CML), polycythemia vera (PV), essential thrombocythemia
(ET), chronic idiopathic myelofibrosis (CIMF), and the related
disorders chronic eosinophilic leukemia (CEL) and idiopathic
hypereosinophilic syndrome (HES) (Table 1). The MPDs each
have an incidence of 1–2 cases per 100,000 population per year.
CML is a hematopoietic stem cell MPD that is invariably
associated with a BCR-ABL fusion gene, usually as a conse-
quence of t(9;22) generating a Philadelphia (Ph) chromosome.
CML is characterized clinically by leukocytosis with overproduc-
tion of maturing neutrophils, and a triphasic clinical course with
chronic, accelerated, and blast crisis stages. Readers are
referred to several recent reviews for detailed discussions of the
biology and therapy of CML (Faderl et al., 1999; Kantarjian and
Talpaz, 2004). Patients with clinical features of CML who lack
the BCR-ABL fusion are designated as “atypical CML” in the
WHO classification, while chronic neutrophilic leukemia (CNL)
is a rare disorder characterized by Ph− clonal overproduction of
mature neutrophils (Table 1).
Since other MPDs have clinical features that can overlap
with CML, the BCR-ABL fusion should be excluded in all
patients. Idiopathic HES is characterized by persistent
eosinophilia (>1500/µl) without secondary causes such as
malignancy, parasitic infection, or allergy, accompanied by end-
organ damage, including the heart and nervous system. Some
HES patients, predominantly male, have clonal eosinophila
often accompanied by anemia, thrombocytopenia, and elevated
serum B12 levels, and probably represent the subset with bona
fide MPD. PV is characterized by inappropriate expansion of
mature erythroid cells with increased hematocrit and red cell
mass, often accompanied by moderate leukocytosis and throm-
bocytosis, splenomegaly, and an elevated risk of arterial and
venous thrombosis. Although no consensus exists for the diag-
nosis of PV, the WHO modification of the original Polycythemia
Vera Study Group criteria is widely used (Tefferi, 2001). Causes
of secondary erythrocytosis such as hemoglobinopathies, ery-
thropoietin-secreting tumors, and congenital polycythemias
must be excluded. BM cytogenetic studies are normal in most
PV patients, with 20%–30% having 20q−, +8, or +9. ET is char-
acterized by increased BM megakaryocytes and circulating
platelets, normal BM cytogenetics, and an increased incidence
of vasomotor symptoms and thrombohemorrhagic events.
Reactive causes of thrombocytosis, including infection, malig-
nancy, and iron deficiency, must be excluded. Lastly, CIMF is
characterized by clonal myeloproliferation with megakaryocytic
hyperplasia accompanied by nonclonal marrow fibroblast
proliferation leading to myelofibrosis and extramedullary
hematopoiesis, usually with marked splenomegaly and anemia.
Risk factors for CIMF include exposure to ionizing radiation,
thorium, and benzene, and clonal cytogenetic abnormalities,
most frequently 13q−, 20q−, and +1q, are seen in 30%–40% of
patients. The non-CML MPDs have a variable tendency to
progress to AML, ranging from 1%–5% in ET and PV to over
20% in CIMF.
Molecular pathogenesis of MPDs
CML is the best understood MPD. BCR-ABL encodes a chimeric
polypeptide that joins N-terminal Bcr sequences to C-terminal
sequences from c-Abl to generate a cytoplasmic Bcr-Abl fusion
tyrosine kinase with constitutively elevated activity. Many lines of
evidence implicate Bcr-Abl as the direct cause of CML. Bcr-Abl-
expressing cells have high levels of cellular tyrosyl phosphopro-
teins and constitutive activation of signaling pathways linked to
proliferation, survival, and resistance to DNA damage, and
expression of Bcr-Abl in murine hematopoietic stem cells
induces CML-like myeloproliferative disease in mice (Kantarjian
and Talpaz, 2004). The causative role of Bcr-Abl in CML was
confirmed by studies of imatinib mesylate (also called Gleevec
or STI571), a 2-phenylaminopyrimidine compound that is a com-
petitive inhibitor of ATP binding to the Abl, c-Kit, and platelet-
derived growth factor receptor (PDGFR) tyrosine kinases.
Imatinib inhibits proliferation and induces apoptosis in Bcr-Abl-
expressing cells, suppresses Ph+ myeloid BM colony formation
(Druker et al., 1996), and induces hematologic and cytogenetic
responses in most CML patients (O’Brien et al., 2003).
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A subset of patients with the myeloproliferative variant of
HES/CEL and elevated serum tryptase levels also respond to
imatinib (Klion et al., 2003; Pardanani et al., 2003b). Cryptic inter-
nal deletions of chromosome 4q12 that fuse PDGFRA with
FIP1L1 are found in most of these patients (Cools et al., 2003a).
A point mutation in the FIP1L1-PDGFRα catalytic domain render-
ing the fusion kinase insensitive to imatinib was identified in a
responding HES patient who relapsed, solidifying its pathogenet-
ic role (Cools et al., 2003b). Systemic mastocytosis (SM), charac-
terized by clonal mast cell proliferation, hepatosplenomegaly, and
urticaria, is classified separately from the MPDs (Vardiman et al.,
2002). However, some patients with SM and eosinophilia respond
to imatinib and express FIP1L1-PDGFRα (Pardanani et al.,
2003a), while others have an activating D816V mutation in c-KIT
and are imatinib-unresponsive (Zermati et al., 2003). Further
molecular genetic studies are required to clarify the relationship
between these clinical syndromes.
In contrast to CML and HES, the caustive molecular defects
in PV, ET, and CIMF are unknown. The central pathophysiologi-
cal abnormality in PV is red cell production that is independent
of erythropoietin (Epo), the hormone that normally regulates
erythropoiesis. In PV, serum Epo levels are low, and BM ery-
throid progenitors form Epo-independent colonies in methylcel-
lulose cultures (Correa et al., 1994). These endogenous
erythroid colonies (EEC) are diagnostic of the disease. The
molecular basis of EEC is unknown, but it is likely to be down-
stream of the cell surface receptor for Epo (Epo-R), which is not
mutated and has normal expression and affinity for Epo. PV ery-
throid cells demonstrate abnormal tyrosine kinase and phos-
phatase signaling, increased expression of Bcl-XL, and
decreased expression of c-Mpl, while aberrant transcription of
PRV-1, a member of the uPAR receptor family (Temerinac et al.,
2000), has been documented in granulocytes from PV patients.
However, none of these abnormalities is diagnostic of or the
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Table 1. WHO classification of MPD and MDS
Disorder Peripheral blood Bone marrow
Myeloproliferative diseases
Chronic myeloid leukemia (CML) Leukocytosis, neutrophilia with left shift, Hypercellular, <5% blasts (chronic phase), no Auer rods, 
basophilia, thrombocytosis, ↓ LAP score Ph+ and/or BCR-ABL+
Chronic neutrophilic leukemia (CNL) Clonal neutrophilia without left shift Granulocytic hyperplasia w/o dysplasia, Ph− and BCR-ABL−
Polycythemia vera (PV) Erythrocytosis w/↓serum Epo, leukocytosis w/ Hypercellular, +endogenous erythroid colonies, Ph−
↑ PRV-1, thrombocytosis, ↑ LAP score and BCR-ABL−
Essential thrombocythemia (ET) Thrombocytosis w/nl hematocrit Megakaryocytic hyperplasia w/o dysplasia, nl Fe stores, 
Ph− and BCR-ABL−
Chronic idiopathic myelofibrosis (CIMF) Anemia w/teardrop erythrocytes, platelets and Nonclonal fibrosis, extramedullary hematopoiesis, Ph−,
leukocytes ↑ or ↓ ± clonal cytogenetic abnl
Chronic eosinophilic leukemia/ Clonal eosinophila >1500/µl Hypercellular with ↑ eosinophil precursors, ± FIP1L1- 
hypereosinophilic syndrome (CEL/HES) PDGFRα fusion, Ph− and BCR-ABL−
Chronic myeloproliferative disease, Leukocytosis with excess myeloid cells Myeloid hyperplasia w/o dysplasia, ± clonal cytogenetic 
unclassifiable abnl [eg t(9;12)]
Myelodysplastic/myeloproliferative syndromes
Chronic myelomonocytic leukemia Monocytes >1000/µl, ± eosinophilia, blasts <5% Dysplasia in 1 or more lineages, <20% blasts, ± clonal 
(CMML) (CMML-1) or 5-19% (CMML-2) cytogenetic abnl [eg t(5;12), t(5;7)]
Juvenile myelomonocytic leukemia Monocytes >1000/µl, blasts <5% Myeloid hyperplasia, GM-CSF hypersensitivity, KRAS2, 
(JMML) NRAS, PTPN11, and NF1mutations
Atypical CML Leukocytosis, neutrophilia, often with anemia/ Often w/dysplasia in neutrophils or multilineage, Ph−
thrombocytopenia and BCR-ABL−
MDS/MPD, unclassifiable Leukocytosis, blasts <5% Hypercellular, dysplasia in 1 or more lineages
Myelodysplastic syndromes
Refractory anemia (RA) Anemia, no or rare blasts Erythroid dysplasia only, <5% blasts, <15% RS
Refractory anemia with Anemia, no blasts Erythroid dysplasia only, <5% blasts, ≥15% RS
ringed sideroblasts (RARS)
Refractory cytopenia with Cytopenia of 2 or 3 lineages, no or rare blasts, Dysplasia >10% of cells in ≥2 myeloid lines, no Auer rods,
multilineage dysplasia (RCMD) no Auer rods, monocytes <1000/µl <5% blasts, <15% RS 
Refractory cytopenia with Cytopenia of 2 or 3 lineages, no or rare blasts, Dysplasia >10% of cells in ≥2 myeloid lines, no Auer rods, 
multilineage dysplasia and ringed no Auer rods, monocytes <1000/µl <5% blasts, ≥15% RS
sideroblasts (RCMD-RS)
Refractory anemia with excess blasts-1 Cytopenias, <5% blasts, no Auer rods, Uni- or multi-lineage dysplasia, 5-9% blasts, no Auer rods
(RAEB-1) monocytes <1000/µl
Refractory anemia with excess blasts-2 Cytopenias, 5-19% blasts, ± Auer rods, Uni- or multi-lineage dysplasia, 10-19% blasts, ± Auer rods
(RAEB-2) monocytes <1000/µl
Myelodysplastic syndrome with del(5q) Anemia, <5% blasts, platelets nl or ↑ Nl to ↑ megakaryocytes w/hypolobulated nuclei, 
<5% blasts, no Auer rods, isolated del(5q)
Myelodysplastic syndrome, Cytopenias, no or rare blasts, no Auer rods Unilineage dyplasia in neutrophils or megakaryocytes, 
unclassifiable (MDS-U) <5% blasts, no Auer rods
Adapted from Vardiman et al., 2002. Copyright American Society of Hematology, used with permission.
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cause of PV. Studies of rare pedigrees of familial PV have sug-
gested a dominant multistep mode of inheritance, involving both
loss- and gain-of-function mechanisms (Kralovics et al., 2003).
Similar to PV, BM megakaryotic precursors (CFU-Meg) from ET
patients form colonies in the absence of exogenous throm-
bopoietin (Tpo), but spontaneous CFU-Meg can also be found
in CML and PV. There is no evidence for mutations in the genes
for c-Mpl or Tpo, and ET patients have normal or even
decreased plasma Tpo levels, possibly reflecting increased Tpo
clearance due to the elevated circulating platelet mass. In CIMF,
the underlying abnormality is clonal hematopoiesis with chronic
myeloproliferation and expansion of atypical megakaryotes that
secrete growth factors, including TGF-β and Tpo, responsible
for BM fibrosis and increased vascularity (Reilly, 1997).
Recent advances in the biology and therapy of MPDs
The therapy of CML is evolving rapidly (reviewed in Kantarjian
and Talpaz, 2004). Imatinib has quickly replaced interferon-alfa
as the treatment of choice in chronic phase CML (O’Brien et al.,
2003), but initial enthusiasm has been tempered by the realiza-
tion that molecular remissions are rare with imatinib (Hughes et
al., 2003), possibly because quiescent Ph+ stem cells are insen-
sitive to the drug (Graham et al., 2002). In addition, acquired
resistance is frequent in advanced CML and can arise from
BCR-ABL gene amplification or from point mutations that ren-
der the kinase less sensitive to the drug (Gorre et al., 2001).
Lastly, there is concern about clonal Ph− cytogenetic abnormal-
ities that develop in some imatinib-treated patients, although
their clinical significance is unknown (Loriaux and Deininger,
2004). Second-generation Abl kinase inhibitors with increased
potency and activity against some imatinib-resistant Bcr-Abl
mutants are in clinical testing (Shah et al., 2004), but drug resis-
tance is likely to be a persistent problem. There is much interest
in identifying signaling pathways contributing to myeloprolifera-
tion and disease progression in CML that could be targeted to
prevent or overcome resistance to Abl kinase inhibitors. Ras,
phosphatidylinositol 3-kinase, and mammalian target of
rapamycin are activated by Bcr-Abl, and drugs inhibiting these
pathways have activity in preclinical models of BCR-ABL
leukemia (Hoover et al., 2002; Mohi et al., 2004). Src family
kinases are also activated by Bcr-Abl and targeted by dual Abl-
Src inhibitors (La Rosee et al., 2002), but may be involved prin-
cipally in blast crisis rather than chronic phase CML (Hu et al.,
2004). Dysregulated Wnt signaling leading to aberrant self-
renewal may contribute to progression of CML to myeloid blast
crisis (Jamieson et al., 2004). Despite the clinical success of
imatinib, allogeneic hematopoietic stem cell transplantation
(alloHSCT) remains the only known curative treatment for CML,
which is due to a potent graft-versus-leukemia (GvL) effect
mediated by donor lymphocytes. Novel approaches to increase
GvL responses include patient vaccination or generation of
donor cytotoxic T cells against antigens such as proteinase-3 or
WT-1 that are overexpressed in CML BM (Molldrem et al.,
2002).
Specific therapy of HES with imatinib should be guided by
molecular studies whenever possible. Imatinib responses often
occur at daily doses as low as 100 mg, reflecting the high sensi-
tivity of PDGFRα to the drug. Some HES patients, particularly
those with elevated serum Troponin T levels, develop acute
myocarditis upon initiation of imatinib therapy (Pardanani et al.,
2003b), which usually responds to corticosteroids.
Therapy of the other MPDs is empiric and largely aimed at
ameliorating symptoms and preventing complications. In PV,
the mainstay of therapy is controlling the hematocrit with phle-
botomy or hydroxyurea to prevent hyperviscosity and stroke.
Low-dose aspirin therapy can decrease the incidence of throm-
botic complications without increasing the risk of hemorrhage
(Landolfi et al., 2004). The anti-megakaryocyte agent anegre-
lide has been used to control thrombocytosis, but there is no
evidence that this affects the incidence of thrombosis. In ET, the
overall prognosis is good, and the mainstay of treatment is pre-
vention of vasomotor and thrombohemorrhagic events by con-
trolling the platelet count with hydroxyurea and/or anegrelide. In
CIMF, the prognosis is much worse, and the only curative treat-
ment is alloHSCT for younger patients, where engraftment is
not a problem despite the marrow fibrosis. The anemia of CIMF
is managed symptomatically with transfusions and iron chela-
tion therapy, while some patients respond to androgens, corti-
costeroids, or thalidomide. Imatinib is generally ineffective in
these MPDs, and new approaches to therapy are needed.
Myelodysplastic syndromes and related chronic myeloid
disorders
Classification, clinical features, and epidemiology of MDS
The wide spectrum of clinicopathologic syndromes and our lim-
ited understanding of molecular pathogenesis have impeded
efforts to accurately classify MDS. The WHO modification of the
original FAB classification system incorporated molecular and
cytogenetic data, defined patients with >20% BM blasts as hav-
ing AML, and created a new category of MDS/MPD overlap that
includes juvenile myelomonocytic leukemia (JMML) and chronic
myelomonocytic leukemia (CMML). The prognosis of MDS
varies widely, and an International Prognostic Scoring System
(IPSS) is useful in predicting outcomes (Greenberg et al.,
1997). MDS will probably continue to be subdivided as the
underlying molecular lesions are discovered.
Table 1 summarizes clinical and pathologic features of the
MDS syndromes.The incidence of MDS rises progressively with
age, and many patients present with symptoms of cytopenia
such as infection, bleeding, or fatigue. In contrast, patients with
proliferative MDS subtypes may have fever, splenomegaly, and
leukocytosis. Rather than the chromosomal translocations that
predominate in AML, chromosomal deletions including mono-
somy 5/del(5q), monosomy 7/del(7q), and del(20q) are detect-
ed in many MDS patients. Whereas most patients with MDS
present with normo- or hypercellular marrows, some have dys-
plasia in the context of reduced cellularity. Demonstrating an
MDS-associated clonal cytogenetic abnormality helps to distin-
guish this syndrome from aplastic anemia. The 8p11 myelopro-
liferative syndrome (EMS) is not explicitly included in the current
WHO classification, but is characterized by myeloproliferation
with eosinophilia and high-grade non-Hodgkin’s lymphoma in
association with balanced translocations of chromosome band
8p11.
Therapy-induced MDS (t-MDS) is a distinct clinicopatholog-
ic entity. Affected patients typically present with cytopenia 3–7
years after receiving alkylating agents and/or radiotherapy to
treat a primary cancer (Smith et al., 2003). BM cytogenetics fre-
quently show monosomy 5/del(5) and/or monosomy 7/del(7).
The prognosis is dismal. Patients treated with topoisomerase II
inhibitors are also at increased risk of developing secondary
myeloid malignancies, but with the notable exception of MDS
patients with t(11;16), most develop de novo AML rather than
MDS (Smith et al., 2003). Children with neurofibromatosis type
1 (NF1) or Noonan syndrome (NS) have an increased incidence
F O C U S
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of JMML, while those with Fanconi anemia (FA), congenital neu-
tropenia (CN), Shwachman Diamond syndrome (SDS), and
familial thrombocytopenia (FTP)/AML syndrome are at
increased risk of developing cytopenic subtypes of MDS.
Molecular pathogenesis of the proliferative subclass of
MDS/MPD
Aberrant signal transduction is strongly implicated in the prolif-
erative MDS subtypes. Myeloid progenitors from JMML patients
are hypersensitive to granulocyte-macrophage colony-stimulat-
ing factor in vitro. The NF1 tumor suppressor gene encodes a
GTPase activating protein that negatively regulates Ras signal-
ing, and the normal NF1 allele is frequently deleted in JMML
cells from children with NF1 (Side et al., 1997). Germline mis-
sense mutations in PTPN11, which encodes the SHP-2 tyrosine
phosphatase, are found in nearly all NS patients with JMML,
while somatic PTPN11 mutations are detected in about 35% of
sporadic JMML (Tartaglia et al., 2003). Some of these mutations
disregulate SHP-2 phosphatase activity by destabilizing an
autoinhibitory interaction, and thereby increase signaling to Ras
and other downstream effectors (Tartaglia et al., 2004). Overall,
?85% of JMML specimens show mutations in KRAS2, NRAS,
NF1, or PTPN11 that are largely mutually exclusive, arguing
strongly that hyperactive Ras initiates this MDS.This is support-
ed by studies of Nf1, Kras, and Ptpn11 mutant mice, all of which
develop myeloid disorders resembling JMML and CMML (Araki
et al., 2004; Braun et al., 2004; Chan et al., 2004; Le et al.,
2004). In CMML, KRAS2 and NRAS mutations are found in
?40% of patients, while other cases of CMML with transloca-
tions involving 5q33 express fusions of platelet-derived growth
factor receptor (PDGFR) β with various partner proteins, includ-
ing TEL (Golub et al., 1994). While activating mutations in the
receptor tyrosine kinase FLT3 are frequent in AML (Gilliland and
Tallman, 2002), they are rare in MDS and usually associated
with leukemic progression. Finally, expression in murine bone
marrow of either EMS- or CML-associated fusions involving the
FGFR1 gene on 8p11 recapitulates the human diseases
(Roumiantsev et al., 2004). This work and previous studies of
Bcr-Abl suggest that engagement of Ras and other pathways
via the adaptor proteins Grb2 and Gab2 plays a central role in
the myeloproliferative phenotype (Sattler et al., 2002). Hence,
as previously suggested by Sawyers and Denny (Sawyers and
Denny, 1994), a central theme underlying CML and the prolifer-
ative MDS subtypes is dysregulated signaling leading to Ras
activation (Figure 1).
Molecular pathogenesis of cytopenic MDS
In contrast to the proliferative subtypes of MDS, we have little
understanding of the pathophysiology underlying peripheral
cytopenia in the context of the hypercellular bone marrow that is
characteristic of RA, RA with ringed sideroblasts or excess
blasts, 5q− syndrome, and t-MDS. MDS BM cells have elevated
levels of apoptosis that might contribute to ineffective
hematopoiesis and cytopenias. Recurrent deletions of 5q31,
7q22, and 20q12 in MDS suggest that loss-of-function of
unidentified myeloid tumor suppressor genes within these chro-
mosomal regions contributes to the pathogenesis of MDS.
Haploid dosage of genes in these intervals might also con-
tribute to MDS, as germline haploinsufficiency of RUNX1 is the
cause of FTP/AML syndrome (Song et al., 1999). Somatic
RUNX1 mutations have also been reported recently in de novo
and therapy-induced MDS, particularly in patients with mono-
somy 7/del(7q) (Harada et al., 2003). Among the inherited MDS
subtypes, the FA pathway is a multicomponent DNA damage
response system (D’Andrea and Grompe, 2003). Mutations in
the ELA2 gene cause most cases of CN (Dale et al., 2000), but
the mechanisms of neutropenia or progression to MDS, which
is often associated with somatic mutations in the G-CSF recep-
tor, are unknown. Mutations in the SBDS gene, encoding a pro-
tein of unknown function, are associated with SDS (Boocock et
al., 2003). Transformation to MDS in FA, CN, and SDS is fre-
quently associated with complete or partial monosomy 7, sug-
gestive of common genetic pathways with sporadic MDS.
Retroviral expression in murine BM of the transcription factor
MLL-CBP, the product of t(11;16) in t-MDS (Lavau et al., 2000),
and of EVI1, a zinc finger protein aberrantly expressed in some
cases of MDS (Buonamici et al., 2004), induces cytopenic
MDS-like syndromes that should provide useful model systems
for further study.
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Figure 1. Aberrant signal transduction in MPD and MDS
Many of the genetic lesions found in MPD and MDS lead to production of
mutant proteins that are components of cellular signaling networks that
modulate Ras-GTP levels (Sawyers and Denny, 1994). Fusion protein-tyro-
sine kinases and the diseases in which they are found are shown at the top.
Myeloproliferation induced by Bcr-FGFR1, Bcr-Abl, and Tel-Abl depends on
direct binding to the adapter protein Grb2, which can activate Ras direct-
ly through Sos or indirectly through Gab2 (Sattler et al., 2002) and SHP-2,
which may inhibit proteins that negatively regulate Ras, such as Ras-GAP
and NF1. Pathways leading to Ras activation from the other fusion kinases
are not yet defined. Activating mutations (purple) in SHP-2 and Ras and
loss (yellow) of NF1 are observed in JMML, CMML, and MDS. Imatinib tar-
gets a subset of the fusion tyrosine kinases (top), while farnesyltransferase
inhibitors (FTI) target the common Ras pathway (bottom) and also likely
inhibit other farnesylated signaling proteins (Downward, 2003).
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Recent advances in the therapy of MDS
The management of MDS must be individualized, and the IPSS
is useful for deciding which patients might benefit from intensive
treatment. Conventional high dose chemotherapy is both toxic
and largely ineffective. AlloHSCT may cure MDS; however, most
patients are poor transplant candidates due to advanced 
age, coexisting disease, or lack of a suitable donor.
Nonmyeloablative alloHSCT is being explored as an alterative.
The response of MDS cytopenias to hematopoietic cytokines is
variable; the combination of Epo and G-CSF induces neutrophil
reponses in most patients and erythroid responses in
40%–45%. While imatinib is effective in cases of CMML with
PDGFRβ fusion proteins (Figure 1), the lack of validated targets
in most types of MDS has limited the development of molecular
therapeutics. Farnesyltransferase inhibitors, which have modest
efficacy, probably do not inhibit Ras signaling in vivo
(Downward, 2003). Aberrant DNA methylation is widespread in
MDS BM specimens, and treatment with methyltransferase
inhibitors may restore a more normal pattern of growth by reac-
tivating genes silenced by epigenetic mechanisms in the MDS
clone. Recently approved by the FDA for MDS, 5-azacytidine (5-
aza) induces hematologic improvements in 60% and delays
progression to AML (Silverman et al., 2002), although there was
a much lower rate of complete remissions (7%). The relation-
ship between alterations in genomic DNA methylation and 
clinical responses to 5-aza in MDS is uncertain. The
immunomodulatory agent Revlimid (CC5013) has significant
erythropoietic remitting activity in low-intermediate risk MDS,
improving anemia and normalizing cytogenetic and dysplasic
features (List et al., 2003). Other therapies that are being
explored in MDS include arsenic trioxide, histone deacetylase
inhibitors, and antiangiogenic agents.
Future challenges
MPD and MDS have played a central role in the evolving para-
digm of defining molecular targets through laboratory analysis
of primary cancer cells, using this knowledge to identify thera-
peutic agents that interfere with target proteins, and monitoring
the biochemical effects of treatment in the malignant cells. A
major challenge in those diseases where the pathogenesis is
understood will be extrapolating the therapeutic responses to
targeted drugs into long-term remissions or cures. This may
demand a combination of targeted therapies, immunotherapy,
and strategies to eliminate the rare population of stem-like neo-
plastic cells that maintain the disease in vivo. For the majority of
MPD and MDS where the underlying defects are not known,
significant progress may depend on identifying the causative
mutations, which will require careful bench-to-bedside studies
of human patients and animal modeling. Translating these
pathophysiological insights into improved treatments will
require new approaches to identify patients who are likely to
benefit from targeted therapies and to enroll them into clinical
trials.
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